Elan Corp of Ireland's indirect wholly-owned subsidiary AthenaDiagnostics has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of its common stock, par value $0.01 per share.
The proposed offering will involve only the sale of a portion of the existing shares of common stock held in Athena by its sole shareholder, Elan Pharmaceuticals. It is anticipated that the offering will start in early-2002, with UBS Warburg LLC as the lead underwriter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze